logo-loader

ResApp Health to reveal clinical study results

Last updated: 20:30 05 Nov 2015 EST, First published: 19:30 05 Nov 2015 EST

au_medical_chart350_563be0ea07ed7

ResApp Health's (ASX:RAP) shares are in pre-open this morning following the ASX granting the company a trading halt.

ResApp requested the halt pending additional clinical study results.

The company is developing smartphone medical applications for the diagnosis and management of respiratory disease.

The halt will remain in place until the opening of trade on Tuesday 10th November 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

56 minutes ago